一款刚迈过临床门槛的新药，真能成为长春高新的救命稻草？
The Implications of My Agentic Successes#Like many who have hopped onto the agent train post-Opus 4.5, I’ve become nihilistic over the past few months, but not for the typical reasons. I actually am not hitting burnout and I am not worried that my programming skills are decaying due to agents: on the contrary, the session limits intended to stagger server usage have unintentionally caused me to form a habit of coding for fun an hour every day incorporating and implementing new ideas. However, is there a point to me writing this blog post and working on these libraries if people will likely just reply “tl;dr AI slop” and “it’s vibecoded so it’s automatically bad”?
。关于这个话题，Line官方版本下载提供了深入分析
01 20天赚一年的钱过去一年，AI行业掀起了新一轮的竞速赛。大厂忙着跑马圈地，初创公司则积极冲刺IPO，就在两个月前，“AI六小龙”中的智谱和MiniMax先后登陆港交所，市值也随之而飙升。
在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
Pakistan and India